Report | Date | Price | |
Commercialising Novel Cancer Technology | 24-May-18 | $0.10 | |
Gearing up for growth | 19-Dec-18 | $0.07 |
Company
First Coverage
Report | Date | Price | |
Commercialising Novel Cancer Technology | 24-May-18 | $0.10 | |
Gearing up for growth | 19-Dec-18 | $0.07 |
Invitrocue Ltd is a world-class innovative life sciences company that specialises in developing ground-breaking 3D cell-based models such as Patient-Derived Organoids from all solid cancers.
By utilizing Onco-PDO test, they perform in vitro drug screenings on PDOs to provide the oncologists with the information to better direct patient therapy and personalized patient treatment.
By enabling assessments of the best ways for drugs to be developed, Invitrocue Ltd impart to the industry valuable knowledge in creating better, faster and more affordable disease treatments, working towards the company’s goal of creating a healthier society by providing patients with the best possible care.